US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Super League Gaming Inc.

3.70

-0.4700-11.27%

Post-market: 3.700.00000.00%19:55 EDT

Volume:46.10K

Turnover:175.97K

Market Cap:3.58M

PE:-0.02

High:4.35

Open:4.28

Low:3.50

Close:4.17

52wk High:196.80

52wk Low:3.25

Shares:968.60K

Float Shares:697.36K

Volume Ratio:2.15

T/O Rate:6.61%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-190.7554

EPS(LYR):-1,128.6039

ROE:-2095.51%

ROA:-85.59%

PB:-1.78

PE(LYR):0.00

Loading ...

Overview Company News Filings

Super League Secures $20 Million in Oversubscribed Private Placement Offering

Super League Announces Additional Close in Private Placement Offering Based on Strong Demand, Securing a Total of $20 Million in Gross Proceeds

THOMSON REUTERS

Bristol Myers’ Sotyktu shows efficacy in arthritis and SLE

Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025

Antengene Presents Latest Preclinical Data of ATG-201 (CD19 x CD3 TCE) at ACR 2025

Super League Shares Climb After Final Private Placement

Press Release: Super League Announces Follow On Close of Private Placement Offering, Securing Total of $17.9 Million

Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence

Super League Announces $15.25 Million Private Placement Led by Strategic Digital Asset Investor Evo Fund, Strengthening Balance Sheet and Fortifying Shareholders Equity to Meet Nasdaq Requirements

THOMSON REUTERS

BRIEF-Super League Enterprise Enters Agreements For Offering 1.7 Mln Shares At $1.00 Each

Super League Enterprise: Files Third Amended and Restated Certificate of Incorporation - SEC Filing

THOMSON REUTERS

Super League Enterprise: Amendment Increases Number of Common Stock From 400 Mln to 750 Mln - SEC Filing

THOMSON REUTERS

Super League Enterprise Inc - Enters Agreements for Offering 1,675,000 Shares at $1.00 - SEC Filing

THOMSON REUTERS

Super League Enterprise Inc. Held Shareholder Meeting

JW Therapeutics Advances SLE Treatment with Promising Phase I Results

Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025

Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025

Super League Enterprise Inc: Announces Strategic Partnership With Automatic Worlds

THOMSON REUTERS

Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine

Press Release: Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia(R) in Japan and Certain Other Markets in the Asia-Pacific Region

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SLE/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SLE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","market":"US","secType":"STK","nameCN":"Super League Gaming Inc.","latestPrice":3.7,"timestamp":1774641600000,"preClose":4.17,"halted":0,"volume":46103,"hourTrading":{"tag":"盘后","latestPrice":3.7,"preClose":3.7,"latestTime":"19:55 EDT","volume":335,"amount":1262.45,"timestamp":1774655759045,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.1127098321342925,"floatShares":697356,"shares":968600,"eps":-190.75543,"marketStatus":"Market Closed","change":-0.47,"latestTime":"03-27 16:00:00 EDT","open":4.28,"high":4.3461,"low":3.5,"amount":175972.3755994,"amplitude":0.202902,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-190.75543,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"listingDate":1551157200000,"exchange":"NASDAQ","adjPreClose":4.17,"preHourTrading":{"tag":"盘前","latestPrice":4.31,"preClose":4.16,"latestTime":"09:12 EDT","volume":1822,"amount":7998.0375906,"timestamp":1774617126985,"change":0.15,"changeRate":0.036058,"amplitude":0.101298},"postHourTrading":{"tag":"盘后","latestPrice":3.7,"preClose":3.7,"latestTime":"19:55 EDT","volume":335,"amount":1262.45,"timestamp":1774655759045,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.148643},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","floatShares":697356,"roa":"-85.59%","roe":"-2095.51%","lyrEps":-1128.603888,"volumeRatio":2.148643,"shares":968600,"dividePrice":0,"high":4.3461,"amplitude":0.202902,"preClose":4.17,"low":3.5,"week52Low":3.25,"pbRate":"-1.78","psRate":"0.31","week52High":196.8,"institutionHeld":0,"latestPrice":3.7,"eps":-190.75543,"divideRate":0,"volume":46103,"delay":0,"ttmEps":-190.75543,"open":4.28,"prevYearClose":7.326,"prevWeekClose":4.7,"prevMonthClose":3.97,"prevQuarterClose":7.326,"fiveDayClose":4.7,"twentyDayClose":3.97,"sixtyDayClose":6.7536},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-27","symbol":"SLE","fiscalQuarterEnding":"2025/12","expectedEps":-3.12,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1774584000000,"reportTimeType":"pre","actualEps":-9.44},{"market":"US","date":"2026-01-23","symbol":"SLE","defaultRemindTime":1769178600000,"type":"split","dateTimestamp":1769144400000,"forFactor":12,"toFactor":1,"ratio":12},{"market":"US","date":"2025-11-13","symbol":"SLE","fiscalQuarterEnding":"2025/09","expectedEps":-2.83,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-2.3},{"market":"US","date":"2025-08-14","symbol":"SLE","fiscalQuarterEnding":"2025/06","expectedEps":-6.8,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":-4.52},{"market":"US","date":"2025-06-23","symbol":"SLE","defaultRemindTime":1750685400000,"type":"split","dateTimestamp":1750651200000,"forFactor":40,"toFactor":1,"ratio":40}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1762833600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SLE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SLE","date":"2026-03-27","current":-0.019397,"percent":0.573529,"low":-0.738945,"twenty":-0.358486,"median":-0.271712,"eighty":-0.210567,"high":-0.044016,"avg":-0.284075,"sd":0.119157,"marketCap":4038966},"quantilePoints":[{"date":"2023-09-15","current":-0.077235,"twenty":-0.086128,"median":-0.080205,"eighty":-0.078423,"marketCap":6401787},{"date":"2023-09-22","current":-0.075989,"twenty":-0.079611,"median":-0.075989,"eighty":-0.069678,"marketCap":6298532},{"date":"2023-09-29","current":-0.074744,"twenty":-0.077567,"median":-0.075367,"eighty":-0.07167,"marketCap":6195277},{"date":"2023-10-06","current":-0.072252,"twenty":-0.076986,"median":-0.074328,"eighty":-0.071255,"marketCap":5988768},{"date":"2023-10-13","current":-0.056058,"twenty":-0.075906,"median":-0.072252,"eighty":-0.068681,"marketCap":4646458},{"date":"2023-10-20","current":-0.059795,"twenty":-0.075491,"median":-0.072252,"eighty":-0.064944,"marketCap":4956222},{"date":"2023-10-27","current":-0.044846,"twenty":-0.075325,"median":-0.071006,"eighty":-0.062951,"marketCap":3717166},{"date":"2023-11-03","current":-0.051075,"twenty":-0.07491,"median":-0.068931,"eighty":-0.055726,"marketCap":4233439},{"date":"2023-11-10","current":-0.053151,"twenty":-0.074494,"median":-0.066439,"eighty":-0.051324,"marketCap":4405530},{"date":"2023-11-17","current":-0.15932,"twenty":-0.07491,"median":-0.066023,"eighty":-0.051324,"marketCap":5300404},{"date":"2023-11-24","current":-0.213857,"twenty":-0.076737,"median":-0.067685,"eighty":-0.052154,"marketCap":7114796},{"date":"2023-12-01","current":-0.221494,"twenty":-0.122932,"median":-0.069346,"eighty":-0.053317,"marketCap":7368896},{"date":"2023-12-08","current":-0.2024,"twenty":-0.203928,"median":-0.072252,"eighty":-0.053898,"marketCap":6733646},{"date":"2023-12-15","current":-0.235497,"twenty":-0.21182,"median":-0.072252,"eighty":-0.054563,"marketCap":7834746},{"date":"2023-12-22","current":-0.217675,"twenty":-0.215894,"median":-0.074536,"eighty":-0.054978,"marketCap":7241846},{"date":"2023-12-29","current":-0.203673,"twenty":-0.216403,"median":-0.075159,"eighty":-0.055227,"marketCap":6775996},{"date":"2024-01-05","current":-0.2024,"twenty":-0.216403,"median":-0.075782,"eighty":-0.055726,"marketCap":6733646},{"date":"2024-01-12","current":-0.210038,"twenty":-0.216403,"median":-0.07765,"eighty":-0.056058,"marketCap":6987746},{"date":"2024-01-19","current":-0.220221,"twenty":-0.217675,"median":-0.090076,"eighty":-0.057553,"marketCap":7326546},{"date":"2024-01-26","current":-0.238043,"twenty":-0.218439,"median":-0.176404,"eighty":-0.060459,"marketCap":7919446},{"date":"2024-02-02","current":-0.263515,"twenty":-0.222258,"median":-0.2024,"eighty":-0.062452,"marketCap":8766869},{"date":"2024-02-09","current":-0.288961,"twenty":-0.22404,"median":-0.203673,"eighty":-0.064279,"marketCap":9613445},{"date":"2024-02-16","current":-0.328423,"twenty":-0.227604,"median":-0.204946,"eighty":-0.06511,"marketCap":10926294},{"date":"2024-02-23","current":-0.31442,"twenty":-0.235497,"median":-0.207492,"eighty":-0.065774,"marketCap":10460445},{"date":"2024-03-01","current":-0.306782,"twenty":-0.258166,"median":-0.208765,"eighty":-0.066522,"marketCap":10206345},{"date":"2024-03-08","current":-0.254591,"twenty":-0.26656,"median":-0.210038,"eighty":-0.067186,"marketCap":8469996},{"date":"2024-03-15","current":-0.225313,"twenty":-0.263003,"median":-0.213857,"eighty":-0.068681,"marketCap":7495946},{"date":"2024-03-22","current":-0.349526,"twenty":-0.275749,"median":-0.21513,"eighty":-0.069346,"marketCap":11628396},{"date":"2024-03-28","current":-0.4417,"twenty":-0.283869,"median":-0.216403,"eighty":-0.069346,"marketCap":13396770},{"date":"2024-04-05","current":-0.367495,"twenty":-0.286708,"median":-0.217039,"eighty":-0.071006,"marketCap":11146112},{"date":"2024-04-12","current":-0.300356,"twenty":-0.297872,"median":-0.218948,"eighty":-0.072252,"marketCap":9109803},{"date":"2024-04-19","current":-0.288,"twenty":-0.297872,"median":-0.220857,"eighty":-0.072252,"marketCap":8735051},{"date":"2024-04-26","current":-0.293245,"twenty":-0.295326,"median":-0.222767,"eighty":-0.072252,"marketCap":8894120},{"date":"2024-05-03","current":-0.294239,"twenty":-0.295326,"median":-0.22404,"eighty":-0.072252,"marketCap":8924269},{"date":"2024-05-10","current":-0.276346,"twenty":-0.294239,"median":-0.22404,"eighty":-0.073498,"marketCap":8381577},{"date":"2024-05-17","current":-0.295605,"twenty":-0.295605,"median":-0.227222,"eighty":-0.074328,"marketCap":8381577},{"date":"2024-05-24","current":-0.265832,"twenty":-0.295326,"median":-0.232951,"eighty":-0.074744,"marketCap":7537390},{"date":"2024-05-31","current":-0.292406,"twenty":-0.294456,"median":-0.235497,"eighty":-0.075076,"marketCap":8290883},{"date":"2024-06-07","current":-0.271353,"twenty":-0.294239,"median":-0.238043,"eighty":-0.075491,"marketCap":7693940},{"date":"2024-06-14","current":-0.252339,"twenty":-0.293643,"median":-0.245044,"eighty":-0.075823,"marketCap":7154833},{"date":"2024-06-21","current":-0.201872,"twenty":-0.292909,"median":-0.238043,"eighty":-0.076487,"marketCap":5723866},{"date":"2024-06-28","current":-0.196825,"twenty":-0.292574,"median":-0.238043,"eighty":-0.076986,"marketCap":5580762},{"date":"2024-07-05","current":-0.214489,"twenty":-0.291076,"median":-0.236984,"eighty":-0.077484,"marketCap":6081608},{"date":"2024-07-12","current":-0.257386,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079183,"marketCap":7297929},{"date":"2024-07-15","current":-0.26748,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079694,"marketCap":7584122},{"date":"2024-08-02","current":-0.322994,"twenty":-0.29019,"median":-0.238043,"eighty":-0.080205,"marketCap":9158186},{"date":"2024-08-09","current":-0.280097,"twenty":-0.291452,"median":-0.25,"eighty":-0.090076,"marketCap":7941864},{"date":"2024-08-16","current":-0.331284,"twenty":-0.291452,"median":-0.254591,"eighty":-0.144836,"marketCap":7941864},{"date":"2024-08-23","current":-0.53758,"twenty":-0.294239,"median":-0.257262,"eighty":-0.15932,"marketCap":12887411},{"date":"2024-08-30","current":-0.506735,"twenty":-0.296227,"median":-0.259657,"eighty":-0.193489,"marketCap":12147969},{"date":"2024-09-06","current":-0.478094,"twenty":-0.298215,"median":-0.261996,"eighty":-0.196158,"marketCap":11461345},{"date":"2024-09-13","current":-0.387888,"twenty":-0.305764,"median":-0.26512,"eighty":-0.200267,"marketCap":9298829},{"date":"2024-09-20","current":-0.279367,"twenty":-0.307264,"median":-0.267321,"eighty":-0.201723,"marketCap":6697270},{"date":"2024-09-27","current":-0.280954,"twenty":-0.305764,"median":-0.2674,"eighty":-0.201872,"marketCap":6735311},{"date":"2024-10-04","current":-0.340548,"twenty":-0.30919,"median":-0.267958,"eighty":-0.202294,"marketCap":8163949},{"date":"2024-10-11","current":-0.449597,"twenty":-0.311325,"median":-0.268116,"eighty":-0.2024,"marketCap":10778189},{"date":"2024-10-18","current":-0.388813,"twenty":-0.315693,"median":-0.269014,"eighty":-0.203418,"marketCap":9321020},{"date":"2024-10-25","current":-0.405078,"twenty":-0.328743,"median":-0.270264,"eighty":-0.203673,"marketCap":9710936},{"date":"2024-10-31","current":-0.447393,"twenty":-0.331576,"median":-0.271783,"eighty":-0.204227,"marketCap":10725354},{"date":"2024-11-08","current":-0.410367,"twenty":-0.346526,"median":-0.273854,"eighty":-0.204806,"marketCap":9837739},{"date":"2024-11-15","current":-0.436374,"twenty":-0.369724,"median":-0.275294,"eighty":-0.204946,"marketCap":10461183},{"date":"2024-11-22","current":-0.261371,"twenty":-0.368039,"median":-0.276231,"eighty":-0.20571,"marketCap":6435212},{"date":"2024-11-29","current":-0.294604,"twenty":-0.364668,"median":-0.276346,"eighty":-0.206728,"marketCap":7253456},{"date":"2024-12-06","current":-0.323013,"twenty":-0.356067,"median":-0.277855,"eighty":-0.207492,"marketCap":7952897},{"date":"2024-12-13","current":-0.312281,"twenty":-0.347526,"median":-0.28005,"eighty":-0.208001,"marketCap":7688663},{"date":"2024-12-20","current":-0.321435,"twenty":-0.346138,"median":-0.280097,"eighty":-0.208765,"marketCap":7914039},{"date":"2024-12-27","current":-0.339269,"twenty":-0.34373,"median":-0.28052,"eighty":-0.20902,"marketCap":8353132},{"date":"2025-01-03","current":-0.336691,"twenty":-0.344526,"median":-0.281632,"eighty":-0.210038,"marketCap":8289664},{"date":"2025-01-10","current":-0.383512,"twenty":-0.351706,"median":-0.282822,"eighty":-0.210038,"marketCap":9442446},{"date":"2025-01-17","current":-0.309808,"twenty":-0.347717,"median":-0.284299,"eighty":-0.211096,"marketCap":7627786},{"date":"2025-01-24","current":-0.310545,"twenty":-0.347233,"median":-0.284972,"eighty":-0.212858,"marketCap":7645920},{"date":"2025-01-31","current":-0.354781,"twenty":-0.353001,"median":-0.285142,"eighty":-0.213857,"marketCap":8735057},{"date":"2025-02-07","current":-0.319937,"twenty":-0.350441,"median":-0.285388,"eighty":-0.213857,"marketCap":7877163},{"date":"2025-02-14","current":-0.31412,"twenty":-0.349224,"median":-0.286351,"eighty":-0.213857,"marketCap":7733942},{"date":"2025-02-21","current":-0.308303,"twenty":-0.349022,"median":-0.286674,"eighty":-0.21411,"marketCap":7590720},{"date":"2025-02-28","current":-0.232681,"twenty":-0.348999,"median":-0.28664,"eighty":-0.214489,"marketCap":5728846},{"date":"2025-03-07","current":-0.21936,"twenty":-0.348284,"median":-0.285948,"eighty":-0.214489,"marketCap":5400869},{"date":"2025-03-14","current":-0.209704,"twenty":-0.347244,"median":-0.285144,"eighty":-0.213941,"marketCap":5163122},{"date":"2025-03-21","current":-0.201444,"twenty":-0.347002,"median":-0.285098,"eighty":-0.212359,"marketCap":4959748},{"date":"2025-03-28","current":-0.230354,"twenty":-0.345822,"median":-0.284304,"eighty":-0.212359,"marketCap":5671557},{"date":"2025-04-04","current":-0.234475,"twenty":-0.342935,"median":-0.283459,"eighty":-0.210567,"marketCap":3900496},{"date":"2025-04-11","current":-0.236161,"twenty":-0.340036,"median":-0.28231,"eighty":-0.212359,"marketCap":3928533},{"date":"2025-04-17","current":-0.236161,"twenty":-0.338893,"median":-0.280718,"eighty":-0.213857,"marketCap":3928533},{"date":"2025-04-25","current":-0.369736,"twenty":-0.338893,"median":-0.280836,"eighty":-0.213857,"marketCap":6150554},{"date":"2025-05-02","current":-0.394848,"twenty":-0.347107,"median":-0.282596,"eighty":-0.213857,"marketCap":6568294},{"date":"2025-05-09","current":-0.347723,"twenty":-0.34901,"median":-0.284084,"eighty":-0.213899,"marketCap":5784365},{"date":"2025-05-16","current":-0.174182,"twenty":-0.348716,"median":-0.282596,"eighty":-0.211859,"marketCap":2897515},{"date":"2025-05-23","current":-0.187657,"twenty":-0.347631,"median":-0.280836,"eighty":-0.209762,"marketCap":2928392},{"date":"2025-05-30","current":-0.243307,"twenty":-0.347723,"median":-0.280836,"eighty":-0.209995,"marketCap":3796802},{"date":"2025-06-06","current":-0.252949,"twenty":-0.347265,"median":-0.280718,"eighty":-0.210038,"marketCap":3947265},{"date":"2025-06-13","current":-0.226363,"twenty":-0.347212,"median":-0.28021,"eighty":-0.210038,"marketCap":3532387},{"date":"2025-06-20","current":-0.204904,"twenty":-0.346791,"median":-0.280097,"eighty":-0.210029,"marketCap":3197521},{"date":"2025-06-27","current":-0.222294,"twenty":-0.344958,"median":-0.279367,"eighty":-0.209283,"marketCap":3468896},{"date":"2025-07-03","current":-0.240225,"twenty":-0.342139,"median":-0.277573,"eighty":-0.209588,"marketCap":3748716},{"date":"2025-07-11","current":-0.314762,"twenty":-0.339781,"median":-0.277296,"eighty":-0.209879,"marketCap":4911855},{"date":"2025-07-18","current":-0.242124,"twenty":-0.33814,"median":-0.276346,"eighty":-0.210021,"marketCap":3778350},{"date":"2025-07-25","current":-0.228831,"twenty":-0.337327,"median":-0.276269,"eighty":-0.210038,"marketCap":3570911},{"date":"2025-08-01","current":-0.243781,"twenty":-0.33696,"median":-0.274358,"eighty":-0.210831,"marketCap":3804205},{"date":"2025-08-08","current":-0.233576,"twenty":-0.336712,"median":-0.273838,"eighty":-0.212858,"marketCap":3644959},{"date":"2025-08-15","current":-0.231876,"twenty":-0.33606,"median":-0.271353,"eighty":-0.213354,"marketCap":3618418},{"date":"2025-08-22","current":-0.221928,"twenty":-0.335323,"median":-0.269787,"eighty":-0.212104,"marketCap":3535981},{"date":"2025-08-29","current":-0.23749,"twenty":-0.333566,"median":-0.269388,"eighty":-0.213354,"marketCap":3783930},{"date":"2025-09-05","current":-0.192157,"twenty":-0.332345,"median":-0.269014,"eighty":-0.213084,"marketCap":3061642},{"date":"2025-09-12","current":-0.207719,"twenty":-0.332042,"median":-0.268116,"eighty":-0.210012,"marketCap":3309592},{"date":"2025-09-19","current":-0.247639,"twenty":-0.331721,"median":-0.267958,"eighty":-0.20982,"marketCap":3945637},{"date":"2025-09-26","current":-0.362878,"twenty":-0.332345,"median":-0.267958,"eighty":-0.210012,"marketCap":5781732},{"date":"2025-10-03","current":-0.272683,"twenty":-0.334082,"median":-0.268394,"eighty":-0.210038,"marketCap":4344654},{"date":"2025-10-10","current":-0.24891,"twenty":-0.332345,"median":-0.268116,"eighty":-0.210567,"marketCap":3965889},{"date":"2025-10-17","current":-0.321134,"twenty":-0.33627,"median":-0.269014,"eighty":-0.211856,"marketCap":5116629},{"date":"2025-10-24","current":-0.188157,"twenty":-0.335429,"median":-0.268704,"eighty":-0.211856,"marketCap":2997912},{"date":"2025-10-31","current":-0.131167,"twenty":-0.334082,"median":-0.267958,"eighty":-0.20982,"marketCap":2089890},{"date":"2025-11-07","current":-0.105839,"twenty":-0.332345,"median":-0.267719,"eighty":-0.208727,"marketCap":1686325},{"date":"2025-11-14","current":-0.110362,"twenty":-0.332042,"median":-0.267321,"eighty":-0.207583,"marketCap":1758390},{"date":"2025-11-21","current":-0.081028,"twenty":-0.331721,"median":-0.26512,"eighty":-0.206427,"marketCap":1285354},{"date":"2025-11-28","current":-0.659255,"twenty":-0.334597,"median":-0.266863,"eighty":-0.206708,"marketCap":10457765},{"date":"2025-12-05","current":-0.720254,"twenty":-0.337177,"median":-0.26748,"eighty":-0.207472,"marketCap":11425396},{"date":"2025-12-12","current":-0.614194,"twenty":-0.34219,"median":-0.267958,"eighty":-0.207492,"marketCap":9742959},{"date":"2025-12-19","current":-0.474574,"twenty":-0.347254,"median":-0.268394,"eighty":-0.207537,"marketCap":7528174},{"date":"2025-12-26","current":-0.4608,"twenty":-0.349022,"median":-0.269014,"eighty":-0.207719,"marketCap":7309663},{"date":"2026-01-02","current":-0.447318,"twenty":-0.351152,"median":-0.26966,"eighty":-0.207719,"marketCap":7095801},{"date":"2026-01-09","current":-0.503223,"twenty":-0.354793,"median":-0.269873,"eighty":-0.208261,"marketCap":7982631},{"date":"2026-01-16","current":-0.526743,"twenty":-0.360917,"median":-0.271353,"eighty":-0.208641,"marketCap":8355727},{"date":"2026-01-23","current":-0.388481,"twenty":-0.368101,"median":-0.272683,"eighty":-0.20874,"marketCap":6162476},{"date":"2026-01-30","current":-0.377954,"twenty":-0.369864,"median":-0.273838,"eighty":-0.208765,"marketCap":5995491},{"date":"2026-02-06","current":-0.254616,"twenty":-0.369341,"median":-0.274166,"eighty":-0.209154,"marketCap":4038966},{"date":"2026-02-13","current":-0.250952,"twenty":-0.368944,"median":-0.274262,"eighty":-0.209588,"marketCap":3980851},{"date":"2026-02-20","current":-0.244846,"twenty":-0.368353,"median":-0.273838,"eighty":-0.20982,"marketCap":3883993},{"date":"2026-02-27","current":-0.219812,"twenty":-0.367557,"median":-0.272683,"eighty":-0.209529,"marketCap":3486877},{"date":"2026-03-06","current":-0.285756,"twenty":-0.365648,"median":-0.271783,"eighty":-0.20982,"marketCap":4532940},{"date":"2026-03-13","current":-0.266522,"twenty":-0.361898,"median":-0.272212,"eighty":-0.210012,"marketCap":4227838},{"date":"2026-03-20","current":-0.285756,"twenty":-0.360355,"median":-0.272267,"eighty":-0.210038,"marketCap":4532940},{"date":"2026-03-27","current":-0.254616,"twenty":-0.358486,"median":-0.271712,"eighty":-0.210567,"marketCap":4038966}],"updateTime":1774708864242},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLE\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2578956035","title":"Super League Secures $20 Million in Oversubscribed Private Placement Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2578956035","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578956035?lang=en_us&edition=fundamental","pubTime":"2025-10-28 20:00","pubTimestamp":1761652816,"startTime":"0","endTime":"0","summary":"Super League Enterprise Inc.  has completed its previously announced private placement financing, securing a total of $20 million in gross proceeds following strong investor demand. The offering included shares of common stock, pre-funded warrants, and warrants to purchase common stock, and was anchored by a $10 million investment from Evo Fund. The company plans to use the net proceeds for working capital, general corporate purposes, debt repayment, and strategic growth initiatives. Aegis Capital Corp. acted as the exclusive placement agent for the offering.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Super League Enterprise Inc. published the original content used to generate this news brief via GlobeNewswire  on October 28, 2025,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nNDLGRSpQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","NDAQ","SLE","IE00BKPKM429.USD","BK4585","IE00BGHQF748.EUR","LU2210150020.SGD","BK4588","IE00B3QW5Z07.USD","LU0314104364.USD","LU2095319765.USD","LU2210149790.SGD","BK4112","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2578595625","title":"Super League Announces Additional Close in Private Placement Offering Based on Strong Demand, Securing a Total of $20 Million in Gross Proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2578595625","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578595625?lang=en_us&edition=fundamental","pubTime":"2025-10-28 20:00","pubTimestamp":1761652801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nTUABB7JRX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2578464865","title":"Bristol Myers’ Sotyktu shows efficacy in arthritis and SLE","url":"https://stock-news.laohu8.com/highlight/detail?id=2578464865","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578464865?lang=en_us&edition=fundamental","pubTime":"2025-10-27 19:12","pubTimestamp":1761563525,"startTime":"0","endTime":"0","summary":"Bristol Myers (BMY) announced Week 52 data from the pivotal Phase 3 POETYK PsA-1 trial further confirming the efficacy and safety of Sotyktu – deuc...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bristol-myers-sotyktu-shows-efficacy-in-arthritis-and-sle-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bristol-myers-sotyktu-shows-efficacy-in-arthritis-and-sle-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1868836757.USD","LU1032466523.USD","BK4588","LU1670711040.USD","LU0985481810.HKD","LU1868836591.USD","LU1093756325.SGD","LU0456855351.SGD","BK4581","LU0096364046.USD","LU0267386448.USD","LU0225284248.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","LU1989771016.USD","IE0002141913.USD","LU2242646821.SGD","BK4007","LU1670710588.SGD","LU0868494617.USD","IE00BSNM7G36.USD","BK4077","LU0321505868.SGD","LU0882574055.USD","LU1261432733.SGD","LU1868836914.USD","LU1670711123.USD","LU0306807586.USD","LU2133065610.SGD","LU2360032135.SGD","BK4532","LU0225771236.USD","SLE","LU1718418525.SGD","LU1323610961.USD","LU2125154935.USD","MYE","LU0237698245.USD","LU1868837136.USD","BMY","BK4126","LU1074936037.SGD","BK4585","LU0306806265.USD","IE00BFTCPJ56.SGD","LU0321505439.SGD","LU1291159041.SGD","BK4534","BK4559","LU2125154778.USD"],"gpt_icon":0},{"id":"2578464805","title":"Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2578464805","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578464805?lang=en_us&edition=fundamental","pubTime":"2025-10-27 19:00","pubTimestamp":1761562800,"startTime":"0","endTime":"0","summary":"– All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS re","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/27/3174441/0/en/Cabaletta-Bio-Presents-Positive-Clinical-Data-and-Development-Updates-for-Rese-cel-at-ACR-Convergence-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","IE00B19Z4B17.USD","BK4110","IE0031619046.USD","IMNM","BK4077","SLE","CABA","CRS","IE00B66KJ199.SGD","IE00B7SZL793.SGD","BK4139","LU0963586101.USD","LU2065731478.USD","BK4006","BK4187","ACR"],"gpt_icon":0},{"id":"2578643636","title":"Antengene Presents Latest Preclinical Data of ATG-201 (CD19 x CD3 TCE) at ACR 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2578643636","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578643636?lang=en_us&edition=fundamental","pubTime":"2025-10-27 09:00","pubTimestamp":1761526800,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Oct. 27, 2025 /PRNewswire/ -- Antengene Corporation Limited , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that the latest preclinical data of ATG-201  were presented in a Poster Presentation at the 2025 American College of Rheumatology  Annual Meeting, taking place from October 24th to October 29th in Chicago, IL, the United States. ATG-201 is a lead program developed using AnTenGager, the company's proprietary T-cell engager  platform which features \"2+1\" bivalent binding for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome  and enhance efficacy.In in vitro studies, ATG-201 demonstrated stronger B cell depletion activity in peripheral blood mononuclear c","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-presents-latest-preclinical-data-of-atg-201-cd19-x-cd3-tce-at-acr-2025-302593957.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IND.AU","LU2065731478.USD","BK4218","PK","BK4006","CRS.AU","BK7096","BK4181","BK4077","ACR.AU","CRS","IE0031619046.USD","SLE","IE00B66KJ199.SGD","BK4187","BK4110","LU0963586101.USD","BK7095","ACR","IE00B19Z4B17.USD","IE00B7SZL793.SGD"],"gpt_icon":0},{"id":"2578216523","title":"Super League Shares Climb After Final Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2578216523","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578216523?lang=en_us&edition=fundamental","pubTime":"2025-10-25 05:39","pubTimestamp":1761341940,"startTime":"0","endTime":"0","summary":"Super League Enterprise shares rose after it said it closed the second and final tranche of its private placement financing.The stock gained 11% to $2.38 in after-hours trading on Friday. Through the close, shares had lost 91% of their value this year.The Santa Monica, Calif., media company has secured $17.9 million in total gross proceeds from new and existing investors, it said. The offering was anchored by the previously announced $10 million investment from Evo Fund and added $2.65 million in the final tranche.Super League will emerge with more than $15 million of deployable capital after accounting for transaction fees, expenses and debt repayments. Management believes that funding will be enough to cover its operations for the foreseeable future.The financing is the culmination of a six-month turnaround plan to eliminate all outstanding debt by next month, streamline capital structure and gain enough capital to fund operations.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2578472065","title":"Press Release: Super League Announces Follow On Close of Private Placement Offering, Securing Total of $17.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2578472065","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578472065?lang=en_us&edition=fundamental","pubTime":"2025-10-25 04:05","pubTimestamp":1761336300,"startTime":"0","endTime":"0","summary":"With Substantial Cash on Balance Sheet, Company Set to Reignite Growth and Drive Shareholder Value on Path to Profitability. SANTA MONICA, Calif., Oct. 24, 2025  -- Super League  , a leader in playable media trusted by global brands to reach and activate gaming audiences through playable ads and gamified content, today announced the closing of the second and final tranche of its previously announced private placement financing. With an additional $2.65 million, the Company has secured $17.9 million in total gross proceeds from new and existing investors. The offering was anchored by the previously announced $10 million investment from Evo Fund.Super League will emerge with more than $15 million of deployable capital after accounting for transaction fees and expenses and debt repayments. Following significant cost reductions and successful revenue diversification implemented in the prior two fiscal quarters, management believes the funding to be sufficient to fund its current operations","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSS","SLE","BK4077","NQmain"],"gpt_icon":0},{"id":"2577071603","title":"Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence","url":"https://stock-news.laohu8.com/highlight/detail?id=2577071603","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577071603?lang=en_us&edition=fundamental","pubTime":"2025-10-23 21:15","pubTimestamp":1761225300,"startTime":"0","endTime":"0","summary":"CARLSBAD, Calif., Oct.  23, 2025  (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of six abstracts at the 2025 American College ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/23/3172126/32920/en/Exagen-Announces-Acceptance-of-Six-Abstracts-at-2025-American-College-of-Rheumatology-Convergence.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4110","ACR","AFG","SLE","BK4117","BK4077","XGN","BK4139","BK4107"],"gpt_icon":0},{"id":"2577319412","title":"Super League Announces $15.25 Million Private Placement Led by Strategic Digital Asset Investor Evo Fund, Strengthening Balance Sheet and Fortifying Shareholders Equity to Meet Nasdaq Requirements","url":"https://stock-news.laohu8.com/highlight/detail?id=2577319412","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577319412?lang=en_us&edition=fundamental","pubTime":"2025-10-23 04:28","pubTimestamp":1761164892,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nTUA99JYJV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4077","SLE"],"gpt_icon":0},{"id":"2577391289","title":"BRIEF-Super League Enterprise Enters Agreements For Offering 1.7 Mln Shares At $1.00 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2577391289","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577391289?lang=en_us&edition=fundamental","pubTime":"2025-10-23 00:06","pubTimestamp":1761149210,"startTime":"0","endTime":"0","summary":"BRIEF-Super League Enterprise Enters Agreements For Offering 1.7 Mln Shares At $1.00 Each Oct 22  - Super League Enterprise Inc SLE.O:SUPER LEAGUE ENTERPRISE INC - ENTERS AGREEMENTS FOR OFFERING 1,675,000 SHARES AT $1.00 - SEC FILINGSUPER LEAGUE ENTERPRISE INC - PROCEEDS TO BE USED FOR DEBT REPAYMENT AND NEW STRATEGY - SEC FILINGSUPER LEAGUE ENTERPRISE: FILES THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION - SEC FILINGSUPER LEAGUE ENTERPRISE: AMENDMENT INCREASES NUMBER OF COMMON STOCK FROM 400 MILLION TO 750 MILLION - SEC FILING ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nFWN3W31WF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2577915923","title":"Super League Enterprise: Files Third Amended and Restated Certificate of Incorporation - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2577915923","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577915923?lang=en_us&edition=fundamental","pubTime":"2025-10-22 23:57","pubTimestamp":1761148620,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nFWN3W31WF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4077","SLE"],"gpt_icon":0},{"id":"2577528391","title":"Super League Enterprise: Amendment Increases Number of Common Stock From 400 Mln to 750 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2577528391","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577528391?lang=en_us&edition=fundamental","pubTime":"2025-10-22 23:57","pubTimestamp":1761148620,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nFWN3W31WF:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2577391563","title":"Super League Enterprise Inc - Enters Agreements for Offering 1,675,000 Shares at $1.00 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2577391563","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577391563?lang=en_us&edition=fundamental","pubTime":"2025-10-22 23:57","pubTimestamp":1761148620,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nFWN3W31WF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2577439155","title":"Super League Enterprise Inc. Held Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2577439155","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577439155?lang=en_us&edition=fundamental","pubTime":"2025-10-22 23:56","pubTimestamp":1761148576,"startTime":"0","endTime":"0","summary":"Super League Enterprise Inc. held a meeting at which shareholders elected Jeff Gehl and Matt Edelman to the board of directors. Shareholders also approved the issuance of common stock and shares underlying certain pre-funded warrants pursuant to an equity purchase agreement. Additionally, shareholders approved amendments to the company's certificate of incorporation, including an increase in authorized common stock and other related changes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Super League Enterprise Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 22, 2025, and is ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nNDL3mwFBw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2577840190","title":"JW Therapeutics Advances SLE Treatment with Promising Phase I Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2577840190","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577840190?lang=en_us&edition=fundamental","pubTime":"2025-10-21 16:37","pubTimestamp":1761035854,"startTime":"0","endTime":"0","summary":"JW (Cayman) Therapeutics Co. Ltd. ( ($HK:2126) ) just unveiled an update. JW Therapeutics has submitted Phase I study data of Relmacabtagene autole...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/jw-therapeutics-advances-sle-treatment-with-promising-phase-i-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/jw-therapeutics-advances-sle-treatment-with-promising-phase-i-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLE","BK4539","LENZ","BK4007","BK4139","BK4077"],"gpt_icon":0},{"id":"2576005922","title":"Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2576005922","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576005922?lang=en_us&edition=fundamental","pubTime":"2025-10-17 20:00","pubTimestamp":1760702400,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Oct.  17, 2025  (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical dat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/17/3168567/0/en/Vor-Bio-Announces-Late-Breaking-Oral-Presentation-of-China-Phase-3-IgA-Nephropathy-Clinical-Study-at-American-Society-of-Nephrology-s-Kidney-Week-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA","LU1223083913.SGD","CDE","SLE","BK4107","BK4017","BK4117","BK4077","LU1223082196.USD","AFG","LU1223082519.USD"],"gpt_icon":0},{"id":"2576503191","title":"Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2576503191","media":"GlobeNewswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576503191?lang=en_us&edition=fundamental","pubTime":"2025-10-17 19:00","pubTimestamp":1760698800,"startTime":"0","endTime":"0","summary":"Preclinical data for CLYM116, anti-APRIL monoclonal antibody, highlight favorable pharmacokinetic and pharmacodynamic profile, supporting development for IgA nephropathy (IgAN) Long-term follow-up cli","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/17/3168527/0/en/Climb-Bio-to-Present-Data-at-American-Society-of-Nephrology-ASN-Kidney-Week-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","BK4107","ITP","BK4117","BK4199","SLE","AFG"],"gpt_icon":0},{"id":"2575974135","title":"Super League Enterprise Inc: Announces Strategic Partnership With Automatic Worlds","url":"https://stock-news.laohu8.com/highlight/detail?id=2575974135","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575974135?lang=en_us&edition=fundamental","pubTime":"2025-10-16 21:03","pubTimestamp":1760619814,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nFWN3VX18F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2575874502","title":"Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2575874502","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575874502?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:00","pubTimestamp":1760616000,"startTime":"0","endTime":"0","summary":"Trial met primary endpoint achieving statistically significant improvement in disease activity, with 67.1% of patients responding with telitacicept versus 32.7% with placebo Dual inhibition of BAFF an","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/16/3167846/0/en/Vor-Bio-Announces-Publication-of-China-Phase-3-Study-of-Telitacicept-in-Systemic-Lupus-Erythematosus-in-The-New-England-Journal-of-Medicine.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","RA","BK4077"],"gpt_icon":0},{"id":"2575594407","title":"Press Release: Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia(R) in Japan and Certain Other Markets in the Asia-Pacific Region","url":"https://stock-news.laohu8.com/highlight/detail?id=2575594407","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575594407?lang=en_us&edition=fundamental","pubTime":"2025-10-16 04:30","pubTimestamp":1760560200,"startTime":"0","endTime":"0","summary":"-- Strengthens Viatris' Presence in Japan With the Addition of Two. Innovative Assets Targeting Areas of Significant Unmet Medical Need. -- Leverages Existing Infrastructure and Expertise in Central Nervous System. \"The acquisition of Aculys Pharma leverages our deep commercial infrastructure in Japan and longstanding expertise in CNS, positioning us to bring these innovative treatments to more patients in need,\" said Corinne Le Goff, Chief Commercial Officer, Viatris. \"The addition of pitolisant and Spydia to our portfolio of innovative products is strategically aligned with our commitment to grow in areas where we can make the greatest impact and is a great example of our business development strategy designed to complement our core strengths in markets across the world.\". Under the terms of the acquisition agreement, Viatris has made an upfront payment to Aculys Pharma shareholders as consideration for the acquisition, with additional considera","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4597","BK4077","BK4232","R","BK4583","BK4588","BK4135","BK4081","VTRS","BK4022","CNS","ESS","BK4215","EMA","SLE","LU1839511570.USD","BK4007","LU2087621335.USD","BK4585"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":5,"totalSize":109,"code":"91000000","status":"200"}]}}